- Conditions
- Mitochondrial Diseases, Obesity
- Interventions
- Tracer-enhanced oral glucose tolerance test (OGTT*), Muscle MRI, Dual energy x-ray absorptiometry (DXA), Questionnaires
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2024
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Myeloma
- Interventions
- Bendamustine, Lenalidomide, Dexamethasone, Aspirin, Prophylaxis, Antibiotic, Biweekly Follow Up, Cyclical Follow Up, Restaging, Post-Treatment Follow Up
- Drug · Other
- Lead sponsor
- Robert Redner, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 22
- States / cities
- Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more
- Conditions
- Breast Cancer, Postmenopausal
- Interventions
- Dual x-ray absorptiometry (DXA), Blood draw, Questionnaire
- Procedure · Behavioral
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Carfilzomib, Dexamethasone, Isatuximab, Pomalidomide, Bone Marrow Biopsy, Bone Marrow Aspiration, Skeletal Survey X-Ray, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging
- Drug · Biological · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Lysosomal Diseases, Gangliosidosis, GM1
- Interventions
- AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam
- Biological · Procedure · Drug + 3 more
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 6 Months to 12 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Interventions
- Talquetamab, Iberdomide, Dexamethasone, Bone Marrow Biopsy
- Biological · Drug · Procedure
- Lead sponsor
- Alfred Chung, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Multiple Myeloma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Iberdomide, Magnetic Resonance Imaging, Patient Monitoring, Positron Emission Tomography, Skeletal Survey X-Ray
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 74
- States / cities
- Irvine, California • Los Angeles, California • Orange, California + 55 more
- Conditions
- Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Belantamab Mafodotin, Daratumumab, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Biospecimen Collection, Skeletal Survey X-Ray, Low Dose Computed Tomography of the Whole Body, Bone Marrow Aspiration, Bone Marrow Biopsy
- Biological · Drug · Other + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Fresolimumab
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Houston, Texas